Boehringer Ingelheim has signed a commercial supply agreement for biotechnology firm BeiGene’s tislelizumab.

Tislelizumab is an investigational humanised monoclonal antibody being developed to bind to the PD-1 receptor known to down-regulate the immune system through prevention of T-cell activation.

Under the agreement, Boehringer will manufacture tislelizumab as part of an exclusive multi-year arrangement in the country.

Boehringer will produce the drug candidate at its biopharmaceutical manufacturing facility in Shanghai under a Marketing Authorization Holder (MAH) trial project initiated by the companies.

Boehringer Ingelheim Biopharmaceuticals (China) general manager Dr Jiali Luo said: “The agreement marks the first biopharmaceutical MAH trial project entering into commercial supply in China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The agreement marks the first biopharmaceutical MAH trial project entering into commercial supply in China.”

“We are confident that our quality competence and contract manufacturing capabilities are best-in-class, and excited to plan for the commercial supply of tislelizumab, which has the potential to help patients with a broad array of cancers as both a monotherapy and in combination with other therapies.”

The supply agreement also provides BeiGene with select preferred rights for capacity expansion in the future by Boehringer in China.

BeiGene founder, CEO and chairman John Oyler said: “In addition to working with Boehringer Ingelheim, we are also building our manufacturing facility for biologics commercial supply in Guangzhou, China, in a joint venture with the Guangzhou Development District, that we expect will further expand our capacity to meet anticipated demand for tislelizumab and other biologics in our pipeline.”